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Abstract
Background: Oxytocin is released in response to a fatty meal. Blockage of the oxytocin receptor led to slower
gastric emptying whereas stimulation resulted in less satiety in healthy volunteers. Patients with diabetes mellitus
and gastroparesis lack oxytocin elevation, and dyspepsia is partly caused by reduced fundus accommodation
causing early satiety and related symptoms. The aim of this study was thus to examine the effect of oxytocin on
gastric emptying, satiety and volume intake in patients with gastrointestinal pathology.
Results: Gastric emptying scintigraphy was performed twice in 12 patients with diabetic gastroparesis, once with
oxytocin and once with saline as intravenous infusions. The patients scored their sensation of satiety using a visual
analogue scale (VAS). The gastric emptying in patients with gastroparesis was prolonged during oxytocin infusion
(p = 0.034) without affecting satiety. A slow satiety drinking test was performed in 14 patients with functional
dyspepsia. The patients scored their satiety every five minutes until maximal satiety was reached, and the total
volume was determined. The VAS was also completed 30 minutes afterwards. The test was performed twice, once
with oxytocin and once with saline as intravenous infusions. There was no difference in satiety scores or volume of
nutrient intake between saline and oxytocin infusions, either before, during or after the meal.
Conclusions: Oxytocin prolongs gastric emptying in patients with diabetes mellitus and gastroparesis, but has no
effect on volume of nutrient intake or satiety and other related symptoms in patients with functional dyspepsia.
Keywords: Diabetes mellitus, Functional dyspepsia, Gastroparesis, Gastric emptying scintigraphy, Slow satiety drink-
ing test
Background
Oxytocin and its receptor are expressed throughout the
gastrointestinal (GI) tract [1,2]. Oxytocin is released in
response to a fatty meal in healthy subjects [3], but
patients with diabetes mellitus and gastroparesis have
been found to lack this response [4]. Furthermore,
administration of the oxytocin receptor antagonist atosi-
ban delayed the gastric emptying in healthy subjects [5].
The effect of oxytocin on human gastric emptying has
not been entirely established, with some studies showing
an accelerated effect after a semisolid meal [6,7] and
others showing no effect after a semisolid or solid meal
[5,8]. In animal trials, studies have shown that oxytocin
increases the gastric emptying time and induces satiety
due to both central and peripheral effects [9-12]. On the
other hand, one animal study has found that oxytocin
increases gastric pressure and contracts gastric muscle
fibers [13]. This dual effect may be explained by oxyto-
cin exerting its effect both via cholecystokinin (CCK)
release and CCK-receptors with subsequent inhibition of
gastric emptying [11,12], and via oxytocin receptors sti-
mulating gastric contraction [13].
The pathophysiology of dyspepsia is not yet comple-
tely known, but one theory is reduced ventricular
accommodation in the fundus leading to various
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any medium, provided the original work is properly cited.symptoms, e.g. early satiety. A slow drinking satiety test
can be used to evaluate the accommodation and any
possible pharmacological effects on accommodation and
symptoms [14,15]. In a previous study in healthy sub-
jects, we found that oxytocin reduced the sensation of
satiety without affecting the volume of food intake or
gastric emptying [8]. Seeing that functional dyspepsia
and gastroparesis are the main clinical syndromes asso-
ciated with gastric motor dysfunction [15], both of these
disorders require further study in relation to oxytocin
and its effects.
The aims of this study were to examine the effect of
oxytocin 1) on the gastric emptying in patients with dia-
betes mellitus and gastroparesis, and 2) on satiety and
volume intake in patients with functional dyspepsia.
Results
Gastric emptying test
The gastric emptying test showed that oxytocin pro-
longed the gastric emptying significantly compared to
saline (Figure 1). Only one patient had longer gastric
emptying time during saline than during oxytocin infu-
sions. Although all patients included had verified gastro-
paresis during the year prior to inclusion, seven had a
normal gastric emptying at the time of the saline trial,
and three in the oxytocin trial. Three of the patients
had normal gastric emptying in both trials.
The fasting blood glucose values revealed no differ-
ences between the saline and oxytocin trials (Table 1).
Also, the visual analogue scale (VAS) scores relative to
start value, 30 and 70 minutes after food intake, did not
differ between the two trials (Figure 2).
There was a statistically significant negative correla-
tion between age and HbA1c (r = -0.68; p = 0.016), but
no correlation between age and T1/2 for saline or oxy-
tocin infusions (p = 0.639 and p = 0.687, respectively).
Neither was there any tendency to correlation between
HbA1c and T1/2 for saline or oxytocin infusions (p =
0.989 and p = 0.610, respectively).
Satiety test
The satiety test showed no difference in the total
volume of nutrient intake between the saline and the
oxytocin infusions (p = 0.149). The satiety scores before,
at maximal satiety and 30 minutes after finishing the
meal did not differ between the saline and the oxytocin
trials (p =0 . 4 8 3 ,p = 0.449 and p = 0.450, respectively).
Figure 1 Oxytocin infusions prolonged the gastric emptying time compared to saline in patients with diabetes mellitus and
gastroparesis (p = 0.034). Values are given as box plots representing median (interquartile range). Wilcoxon’s test.
Table 1 Laboratory characteristics of patients with
diabetes mellitus and gastroparesis
Parameter Value
Diabetes duration (years) 32.0 (15.5-39.3)
BMI (kg/m
2) 25.8 (22.4-30.0)
HbA1C (mmol/mol) 64.0 (59.0-68.8)
Fasting blood glucose, saline trial (mmol L
-1) 9.3 (7.1-12.2)
Fasting blood glucose, oxytocin trial (mmol L
-1) 9.6 (6.9-10.5)
BMI = body mass index, HbA1c = glycosylated hemoglobin. Values are given
as median (interquartile range).
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under curve (AUC) for the satiety scores up until this
time was calculated, and no significant difference was
seen (Figure 3; p = 0.953).
The degree of abdominal pain, nausea, abdominal full-
ness and bloating, registered in the VAS symptoms form
30 minutes after finishing the meal did not differ
between the saline and oxytocin infusions (p = 0.735, p
= 0.374, p = 0.674 and p = 0.735, respectively).
When dividing the group of patients with functional
dyspepsia into those with and those without predomi-
nantly early satiety, no differences in volume of nutrient
intake, satiety scores before, during and 30 minutes
after, nor in the registered symptoms after the test were
found (data not shown).
Discussion
This study showed that oxytocin prolonged the gastric
emptying time in patients with diabetes mellitus and
gastroparesis, but did not affect the volume of nutrient
intake in patients with functional dyspepsia. Oxytocin
infusion did not result in lower satiety compared to sal-
ine infusion.
Gastroparesis is a disorder in which the gastric empty-
ing is delayed without mechanical obstruction [16]. The
pathophysiology is multifactorial, with the following
pathologies recognized to date: vagal parasympathetic
dysfunction, hyperglycemia, loss of enteric neurons, loss
of neuronal nitric oxide expression, smooth muscle
abnormalities and disruption of interstitial cells of Cajal
networks [17-19].
Previous studies have shown that the oxytocin recep-
tor antagonist atosiban prolonged gastric emptying in
healthy subjects [5] and diabetic patients with gastropar-
esis lacked an elevation of the oxytocin plasma concen-
tration postprandially compared to patients without
gastroparesis [3,4]. These findings gave rise to the
hypothesis that oxytocin may have an essential role in
GI motility, especially gastric emptying. However, we
could not see any effect of oxytocin on the gastric emp-
tying [5,8]. This may be explained by the dual effect
oxytocin evokes on normal GI physiology. First, a direct
effect of oxytocin on its receptors leads to stimulation
of gastric muscle contraction [13]. Secondly, as oxytocin
stimulates to CCK release, an indirect action via CCK
receptors are activated, leading to inhibition of gastric
emptying [11,12]. As atosiban only blocks the oxytocin
receptor, delayed gastric emptying was seen during the
administration of this specific drug [5].
In the present study, oxytocin prolonged gastric emp-
tying in diabetic gastroparesis. The previously observed
lower oxytocin concentration in plasma in patients with
Figure 2 There were no differences between saline and oxytocin in the VAS scores at 30 and 70 minutes after food intake during
gastric emptying scintigraphy in patients with diabetes mellitus and gastroparesis (p = 0.594 respective p = 0.799). Values are given as
boxplots representing median (interquartile range). Wilcoxon’s test.
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primary etiology of the delayed gastric emptying [4]. It
is plausible that the oxytocin receptor pathway is
destroyed before the CCK receptor pathway, leading to
a loss of contractory stimulation by oxytocin but with a
preserved inhibition by the CCK receptors [11-13]. Ten-
sion of the gastric wall gives rise to afferent signals to
the brain [20]. As oxytocin further delays gastric empty-
ing in a dysfunctional stomach, this may lead to a
reduced oxytocin secretion from the hypophysis by a
feedback mechanism involving the hypothalamus [21].
Oxytocin exerts both peripheral and central effects on
the GI tract as it passes the blood brain barrier [22].
However, the latter pathway is not the primarily by
which oxytocin affects gastric motility, which has been
f o u n dw h e no x y t o c i na n do x y t o c i na n t a g o n i s t sh a v e
been given centrally [23]. It would be interesting to
examine the effect of atosiban in gastroparesis, but this
drug elevates blood glucose levels and could not be used
on patients with diabetes mellitus for ethical reasons.
The effect of the CCK receptor antagonist loxiglu-
mide, which blocks the inhibitory effects on gastric
emptying [24], would also be an interesting drug to
study in this context. In healthy subjects, an intravenous
infusion of loxiglumide stimulated antral contraction
and decreased the gastric emptying half time [25]. The
R-isomer of loxiglumide, dexloxiglumide, has been
tested on patients with functional dyspepsia [26] and
functional constipation [27] but not on patients with
gastroparesis. In functional dyspepsia, the CCK-receptor
antagonist counteracted the increase in gastric volume
and dyspeptic symptoms during duodenal lipid infusion,
while also reducing gastric compliance [26]. However,
the effect on functional constipation has been inconclu-
sive [27].
Oxytocin has in a previous study been shown to be
efficient in the treatment of functional abdominal pain
and depressed mood [28]. This, together with the
described analgesic effect by oxytocin in rats [29], make
oytocin analogs to be promising drugs in the future
treatment of irritable bowel syndrome (IBS) and depres-
sion. The present results of prolongation of gastric emp-
tying by oxytocin underlines the importance of treating
IBS patients with oxytocin or its newly developed ana-
logs, first when GI dysmotility has been excluded.
Patients who have symptoms from the upper GI tract
in the absence of any organic disease are diagnosed as
suffering from functional dyspepsia [30]. Dyspepsia is
one of the most common disorders in the GI tract. The
findings of cellular pathology in dyspepsia are very
sparse, among which a few studies have suggested an
increased amount of gastric mast cells, eosinophil degra-
nulation and afferent dysfunction [31,32]. Other studies
have shown hypersensitivity in the GI tract to mechani-
cal gastric distension, suggesting enhanced perception of
physiological signals [33-35].
Reduced ventricular accommodation after meal intake
has been described in 40% of patients with dyspepsia
[36]. According to Tack et al. [37] reduced accommoda-
tion is associated with early satiety, making it an impor-
tant symptom in this subgroup of patients. The slow
drinking satiety test has been developed to measure ven-
tricular accommodation to a meal and is therefore parti-
cularly suitable for studying this subgroup [14,15].
A previously performed study by our group showed
that oxytocin reduces the sensation of satiety without
affecting the volume of nutrient intake or gastric empty-
ing in healthy subjects [8]. Thus, it could possibly affect
Figure 3 The area under the curve (AUC) for the satiety scores
between saline (a) and oxytocin (b) infusions in patients with
functional dyspepsia did not differ (p = 0.953). Values are given
as boxplots representing median (interquartile range). The square
inside the boxplot represents mean value. Wilcoxon’s test.
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from functional dyspepsia, why we performed the satiety
test on these patients. Interestingly, we could not find a
difference in satiety, volume intake, abdominal pain,
nausea, abdominal fullness and bloating in these patients
with oxytocin versus saline. Satiety was not either
affected during the gastric emptying test. We have pre-
viously described that oxytocin decreases abdominal
pain and depression in patients with functional disor-
ders, but has no effect on constipation [28]. Thus, oxy-
tocin seems to have some effects on sensory functions
but is not efficient in the treatment of GI dysmotility
and symptoms related to the dysmotility. The effect on
abdominal pain in IBS may be explained by that the
pain experience in IBS, and pain relief of oxytocin, are
predominantly central effects [29,38], whereas effects
rendering early satiety may predominantly be of periph-
eral characters [23,37].
One of the limitations of the present study is that
although all patients were recently diagnosed as suffer-
ing from gastroparesis, some of them had normal gastric
emptying in the present study. This may partly be
explained by the variation in the GI motility from one
day to another [39]. Further, hyperglycemia prolongs
gastric emptying [40], and the patients may have been
in better metabolic control at the time when they
entered in the present study, than at the time of their
last gastric emptying scintigraphy. Nevertheless, the
patients cannot be considered to have normal gastric
function as they have had clinical symptoms of dysfunc-
tion leading to admission for gastric scintigraphy, and
have once been classified as gastroparetic by the same
method. Another limitation is the small sample size,
which depends on difficulties to recruite patients in a
good metabolic control. The female predominance in
the study depends on that these disorders are more
common in women than in men [17,41].
Conclusion
Oxytocin prolongs gastric emptying in patients with dia-
betes mellitus and gastroparesis, but has no effect on
volume of nutrient intake or satiety and other related
symptoms in patients with functional dyspepsia.
Methods
The study has been performed according to the Declara-
tion of Helsinki, and was approved by the Ethics Com-
mittee at Lund University and the Swedish Medical
Agency (Dnr 2009/502). Written, informed consent was
obtained from all participants. All of the subjects com-
pleted the tests and no adverse events were reported
apart from a few patients suffering from headaches.
Trial registration: NCT01152047, NCT00776360.
Subjects
Patients with diabetes mellitus and gastroparesis, verified
by an earlier gastric emptying scintigraphy during the
previous year, were invited to undergo gastric emptying
scintigraphy on two occasions, one with saline and one
with oxytocin infusion, with at least 2 days in between.
The patients were recruited from the Department of
Endocrinology, Department of Clinical Sciences, Divi-
sion of Gastroenterology and one primary health care
centre in Malmö.
Exclusion criteria were age < 18 years or > 65 years
and severe complications or cardiac symptoms, which
m a yh a v ee n t a i l e dp o s s i b l er isks of side effects. Twelve
patients (10 women), median age of 56.5 (52.0-64.8)
years, in good metabolic control accepted to participate
in the study. Glycosylated hemoglobin (HbA1c) was
analysed at the Department of Chemistry, Skåne Univer-
sity Hospital, Malmö, according to clinical routines.
HbA1c values were collected as Mono-S and subse-
quently converted to the National Glycohemoglobin
Standardization Program (NGSP) standard by use of the
following algorithm: 0.923 × HbA1c (Mono-S) × 1.345 =
HbA1c (NGSP) [42]. Percentage HbA1c values were con-
verted to the International Federation of Clinical Chem-
istry (IFCC) standard in mmol/mol according to the
following equation: IFCC (mmol/mol) = ([NGSP (%)] -
2,152)/0.09148 [42].
Ten of 12 patients had other diabetic complications
aside from gastroparesis, with retinopathy being the
most common (Table 2). For further patient characteris-
tics see Tables 1 and 2.
Patients with functional dyspepsia were invited to per-
form a slow drinking satiety test on two occasions, one
with saline and one with oxytocin infusion. All patients
with dyspepsia fulfilled the Rome III criteria for func-
tional dyspepsia [41]. They were recruited by advertise-
ment or from a primary health care centre in Malmö.
The most predominant symptoms were registered
(Table 3). Exclusion criteria were age < 18 years or > 65
years, any other organic GI disorder or other severe dis-
eases. Fourteen patients (12 women), median age of 37.5
(24.0-44.5) years, accepted to participate. None of the
patients were using any drugs affecting GI motility.
Visual analogue scale (VAS)
The patients were asked to complete a questionnaire
grading their hunger and/or feeling of satiety, using the
VAS satiety scores graded from 0, for the most extreme
hunger, to 20, for the most extreme satiety [5,8]. The
VAS scale was labeled with different descriptions of
hunger and satiety, from painful hunger to satiety com-
bined with nausea, making it more illustrative. The
patients’ score at baseline was set to zero, and the values
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scale was used in both the gastric emptying- and the
slow drinking satiety test.
Drugs
The subjects were examined on two different occasions
and were given either an infusion of physiological saline
or of oxytocin in random order during the experiments.
Syntocinon
© (Novartis, Täby, Sweden), a synthetic ana-
log of oxytocin, at a concentration of 8.3 μgm L
-1 was
dissolved in 1000 ml saline and given as intravenous
infusions for the duration of the experiment. The oxyto-
c i ni n f u s i o nw a sg i v e na tc o n c e n t r a t i o n so f8 0a n d4 0
mU min
-1, respectively. These doses were chosen, as
they were the most efficient in dose-response trials per-
formed previously in healthy volunteers, and rendered
pharmacological plasma concentrations of oxytocin [8].
Both the patients and the staff performing the gastric
emptying and satiety tests were unaware of which infu-
sion was being given.
Gastric emptying test
The patients were studied in the morning after an over-
night fast. Patients on regular medication influencing GI
motility were asked to stop this treatment two days
before the scintigraphy test. Blood glucose was mea-
sured before the start of the experiment. If b-glucose
was > 18 mml L
-1 the experiment was stopped and the
patient was sent home. When b-glucose was > 12 mmol
L
-1, the patients were given half of their ordinary insulin
dosage at the laboratory before the start of the
experiment.
A test meal was prepared by adding tin colloid labeled
with 30-50 Mbq of
99 mTc to an egg, which was
whipped in a glass cup in a hot water bath until coagu-
lated. The egg and a slice of toasted white bread were
cut into pieces smaller than 1 × 1 cm and served with
100 ml 37°C water. The meal was eaten within five min-
utes. Immediately thereafter a large-field double-headed
gamma camera (Philips Skylight, Philips Medical Sys-
tems, Best, The Netherlands) was placed anteriorly and
posteriorly parallel to the upper abdominal wall. The
radioactivity was measured continuously (1-min frames)
for 70 minutes starting immediately after meal ingestion.
A Region of Interest (ROI) representing the stomach
was created and the activity of the first frame was taken
as 100%. The gradual decreasing radioactivity, measured
as the number of radioactivity decays per minute
(counts/min), was plotted against time. The time elapsed
to reach a 50% decrease of the activity in the ROI (T1/
2) was identified as the point at which this plot crossed
t h e5 0 %v a l u e .T h ev a l u e so ft h er a d i o a c t i v i t ym e a s u r e d
were corrected for the half-life of
99 m Tc, and for
attenuation by using the geometrical mean values of the
decay curves obtained from the two gamma camera
heads used. T1/2 > 2 standard deviations (SD) for
healthy control subjects (70 min) was considered abnor-
mal [43].
An infusion of either saline or 80 mU oxytocin min
-1
was started at the same time as the meal intake began,
and was given throughout the experiments. The subjects
also scored their satiety using a VAS score, at time 0
when the meal intake began, and 30 and 70 minutes
after the meal intake. The gastric emptying time and
VAS scores were used for statistical calculations.
Satiety test
The satiety test was performed according to a previously
developed protocol by Tack et al. [14], using a slightly
modified VAS scale which has been used in other stu-
dies performed by our group [5,8]. The patients were
studied in the morning after an overnight fast. A peri-
staltic pump filled one of two beakers at a rate of 15 ml
min
-1 with a liquid meal consisting of 13% protein, 48%
carbohydrate and 39% lipids (Nutridrink
©; Nutricia, Bor-
nem, Belgium), giving 1.5 kcal ml
-1. The patients were
requested to maintain their intake at the filling rate,
alternating the beakers as they were filled and emptied.
The participants were instructed to terminate their meal
Table 2 Clinical characteristics of patients with diabetes
mellitus and gastroparesis (n = 12)
No (%)
Diabetes mellitus type 1 9 (75)
Diabetes mellitus type 2 3 (25)
Women 10 (83)
Men 2 (17)
Other complications of diabetes mellitus 10 (83)
- Retinopathy 8 (67)
- Peripheral neuropathy 7 (58)
- Nephropathy 2 (17)
- Other 7 (58)
Pharmacological treatment for gastrointestinal dysmotility 4 (33)
Insulin treatment 10 (83)
Oral hypoglycemic drugs 3 (25)
Hypothyroidism 3 (25)
Table 3 Clinical characteristics of patients with functional




Bloating as predominant symptom/symptoms 5 (36)
Early satiety as predominant symptom/symptoms 6 (43)
Epigastric pain as predominant symptom/symptoms 2 (14)
Epigastric burning as predominant symptom/symptoms 2 (14)
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continue to drink any more. At the start of the experi-
ment and at five-minute intervals, they recorded their
satiety using the VAS until they terminated their meal.
A further VAS score for satiety and a separate VAS to
score other GI symptoms, namely, abdominal pain, nau-
sea, abdominal fullness and bloating, were completed 30
minutes after the end of the meal. An infusion of saline
or 40 mU oxytocin min
-1 was started at the same time
as the meal intake began and was terminated when the
meal was ended. The volume of nutrient intake and
registered VAS scores were used in the statistical
calculations.
Statistical analyses
Values are given as median (interquartile range, IQR).
The VAS scores relative to baseline and AUC for VAS
scores were calculated. Statistic differences in gastric
emptying time and related VAS scores in the gastric
emptying test and differences in satiety scores, AUC for
VAS, volume of nutrient intake and VAS scores for GI
symptoms in the satiety test were determined using Wil-
coxon’s test. Correlations were determined using Spear-
man’s test. P < 0.05 was considered statistically
significant.
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